Treatment of ocular inflammatory conditions with loteprednol etabonate
about
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular PressureTherapeutic Strategies to Treat Dry Eye in an Aging PopulationLoteprednol and tobramycin in combination: a review of their impact on current treatment regimens.Pharmacotherapy for uveitis: current management and emerging therapy.Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgeryRecent patents and emerging therapeutics in the treatment of allergic conjunctivitis.Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.Silibinin treatment prevents endotoxin-induced uveitis in rats in vivo and in vitro.Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.New agents for treating dry eye syndrome.Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.Pharmacokinetic evaluation of diquafosol tetrasodium for the treatment of Sjögren's syndrome.Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?Melatonin As A Therapeutic Resource For Inflammatory Visual Diseases.A Prospective, Open-label Study to Compare the Efficacy and the Safety of Topical Loteprednol Etabonate and Topical Flurbiprofen Sodium in Patients with Post-Operative Inflammation after Cataract ExtractionTreating ocular surface disease: new agents in developmentThe Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome.Management of chronic ocular sarcoidosis: challenges and solutions.
P2860
Q26764956-0ED9B77A-EBC3-481C-90B9-273747DD74F6Q26822610-FBACBA39-E80B-4EA5-91A3-687EB6E7E40BQ33538277-A5BD4F83-753C-4191-A315-ADFFA6ACD620Q34274075-E9B4C28A-F69F-49AE-871A-7A026E88223AQ34606700-41B8A13E-2C4D-468B-AF4E-E5B3596E8208Q35187578-20893F86-E2A0-4782-AEF9-C539FBA8BDA4Q36252489-6033046C-6BEC-4BCB-AA21-B54978B61C21Q36334208-2B2561F2-63B8-4056-B833-5BD4FD88F2D5Q38019465-33D50221-F9AD-455D-A945-840811BE31BFQ38058002-7838E11F-C286-49B1-8652-A7A0064001E0Q38112375-51967F14-C0F9-4504-B8A0-3BAF62629C0FQ38209468-BB978442-695A-4C43-B704-23E7243D943AQ38241140-505172BA-2633-40B4-B432-5819A1867059Q39089092-301FB241-BBC3-41A4-B20A-622522C73501Q42102961-82BA33C6-32A0-476F-BCE5-3F137607465DQ42729437-C902AA7D-18EA-468A-B7BB-B25E41674914Q48344821-E2E54322-D649-4612-93D3-07164E09D3DFQ52338865-04FF3583-9672-4FA5-85D1-011E927CF84A
P2860
Treatment of ocular inflammatory conditions with loteprednol etabonate
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Treatment of ocular inflammatory conditions with loteprednol etabonate
@ast
Treatment of ocular inflammatory conditions with loteprednol etabonate
@en
Treatment of ocular inflammatory conditions with loteprednol etabonate
@nl
type
label
Treatment of ocular inflammatory conditions with loteprednol etabonate
@ast
Treatment of ocular inflammatory conditions with loteprednol etabonate
@en
Treatment of ocular inflammatory conditions with loteprednol etabonate
@nl
prefLabel
Treatment of ocular inflammatory conditions with loteprednol etabonate
@ast
Treatment of ocular inflammatory conditions with loteprednol etabonate
@en
Treatment of ocular inflammatory conditions with loteprednol etabonate
@nl
P356
P1476
Treatment of ocular inflammatory conditions with loteprednol etabonate
@en
P2093
C E Pavesio
H H Decory
P356
10.1136/BJO.2007.132621
P407
P577
2008-04-01T00:00:00Z